Multiple Sclerosis Journal · 2013 · 49 citations · 7 references
PharmacyNeurologyPharmacotherapyClinical PharmacologyFunctional RestorationNeuroimmunologyDemyelinating DisordersHealth Status MeasurementHealth-related Quality Of LifeHealth-related Quality Of Life MeasurementMultiple SclerosisMultiple Sclerosis PharmacotherapyFumarate TherapyMultiple Sclerosis Symptom ManagementMultiple Sclerosis TherapyOral TreatmentRelapse TreatmentRelapsing-remitting Multiple Sclerosis Treatment
Multiple sclerosis (MS) has a significant impact on health-related quality of life (HRQoL) with symptoms adversely affecting many aspects of everyday living. BG-12 (dimethyl fumarate) demonstrated significant efficacy in the phase III studies DEFINE and CONFIRM in patients with relapsing-remitting MS. In CONFIRM, HRQoL was worse in patients with greater disability at baseline, and who relapsed during the study, and improved with BG-12 treatment. Mean Short Form-36 Physical Component Summary scores for BG-12 increased over 2 years and scores for placebo decreased. Coupled with clinical and neuroradiological benefits, these HRQoL results further support BG-12 as an effective oral treatment for relapsing MS.
7
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Ralf Gold, Ludwig Kappos, Douglas L. Arnold et al. · New England Journal of Medicine · 2012 · 1.7K citations · Full text
Medicine, Neurology, Pharmacotherapy +17
Quality of Life in Multiple Sclerosis
Richard A. Rudick · Archives of Neurology · 1992 · 246 citations
Health‐related quality of life in multiple sclerosis: effects of natalizumab
Richard A. Rudick, Deborah Miller, Michael Hutchinson et al. · Annals of Neurology · 2007 · 194 citations